Which GMP Requirements Apply to Stability Studies in the Pharmaceutical Industry?

Stability studies are the scientific cornerstone for understanding how the quality of an active substance or medicinal product evolves over time when exposed to environmental factors such as temperature, humidity, and light. Thoughtfully designed and consistently executed stability programs are essential – not only to meet regulatory expectations, but also to support robust lifecycle management and enable confident, risk-based decision-making.

Regulatory Framework

In the European Union, stability studies are anchored in the EU GMP Guide, Part I (Medicinal Products) and Part II (Active Substances).

Chapter 6 (“Quality Control”) of Part I establishes the core regulatory requirements for stability programs, including:

• A written stability program
• Defined storage conditions
• Appropriate testing intervals
• Trend analysis

In addition, an ongoing stability program is required to continuously monitor the stability of marketed products. This program ensures that the shelf life approved during the marketing authorisation procedure remains justified under routine manufacturing conditions.

For active substances, Part II of the EU GMP Guide applies, in particular:

• Chapter 11.5 – Stability Monitoring of APIs
• Chapter 11.6 – Expiry and Retest Dating
• Chapter 17.5 – Stability

These sections require that retest dates or expiry dates for active substances be established on the basis of appropriate stability data.

Another key regulatory aspect concerns technical infrastructure. Stability chambers are subject to the requirements of Annex 15 of the EU GMP Guide (Qualification and Validation). They must undergo appropriate qualification activities (DQ, IQ, OQ, PQ), be periodically requalified, and be continuously monitored. Where stability data are electronically generated, processed, or stored, Annex 11 (Computerised Systems) applies in addition.

In the United States, the regulatory basis is set out in the Code of Federal Regulations (CFR), particularly:

• 21 CFR 211.166 – Stability Testing
• 21 CFR 211.137 – Expiration Dating

Section 211.166 requires a written stability testing program that defines storage conditions, testing intervals, and appropriate analytical methods. The analytical procedures must be stability-indicating, meaning they are capable of detecting changes in the drug product over time.

Section 211.137 governs the assignment of expiration dates and requires scientific justification based on valid stability data.

The World Health Organization (WHO) has issued internationally recognised guidance documents on stability testing, including:

• Technical Report Series, No. 953, 2009, Annex 2: Stability testing of active pharmaceutical ingredients and finished pharmaceutical products
• Technical Report Series 1010, 2018, Annex 10: WHO guidelines on stability testing of active pharmaceutical ingredients and finished pharmaceutical products

ICH – International Harmonisation

Through the guidelines of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), stability requirements have been harmonised across the EU, the United States, and Japan. Although ICH guidelines are not legally binding per se, they are implemented within regional regulatory frameworks and are therefore effectively mandatory in practice.

Currently applicable guidelines include:

• ICH Q1A(R2) – Stability Testing of New Drug Substances and Products
• ICH Q1B – Photostability Testing of New Drug Substances and Products
• ICH Q1C – Stability Testing for New Dosage Forms
• ICH Q1D – Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products
• ICH Q1E – Evaluation of Stability Data

Biotechnological and biological products require additional consideration. In this context, ICH Q5C applies:

• ICH Q5C – Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products

ICH Q1A(R2) represents the primary guideline for stability testing. It defines standard storage conditions for long-term, intermediate, and accelerated studies, outlines the general study design, and specifies the minimum stability data required at the time of marketing authorisation. It also provides guidance on establishing shelf life, storage statements, and the number of batches to be included in stability studies.

ICH Q1B addresses photostability testing, including exposure conditions, required light intensity, and assessment of primary and secondary packaging with regard to light protection.

ICH Q1C applies to new dosage forms and supplements the requirements of Q1A(R2) when an approved active substance is developed in a new formulation or route of administration. Depending on the development stage, reduced or adapted stability programs may be scientifically justified.

ICH Q1D allows reduced study designs such as bracketing and matrixing, provided that scientific justification and an appropriate risk assessment are documented in the regulatory dossier.

ICH Q1E describes the statistical evaluation of stability data, including the use of linear regression models to establish shelf life and the conditions for extrapolation beyond the observed data period. It also defines criteria for assessing significant trends and for pooling data from multiple batches.

Draft ICH Q1 Guideline

On 11 April 2025, a draft revised ICH Q1 Guideline titled “Stability Testing of Drug Substances and Drug Products” was published.

The draft guideline represents a comprehensive revision and consolidation of the existing ICH Q1A–Q1F guidelines as well as ICH Q5C. It expands the scope to include both synthetic and biological drug substances and drug products – including vaccines, gene therapies, and combination products – and introduces a lifecycle-oriented stability management approach aligned with the principles of ICH Q12 (Pharmaceutical Product Lifecycle Management).

The draft addresses all climatic zones in order to further enhance global harmonisation. It also allows application of its principles during clinical development and for reference standards. As with other recent ICH developments, Quality by Design (QbD) and risk management principles (ICH Q8–Q11) play a central role in defining and justifying stability strategies.

Practical Implementation

Each stability study must be conducted according to an approved protocol that defines:

• Product description and batch identification
• Container-closure system
• Storage conditions (e.g., 25°C/60% RH, 30°C/65% RH, 40°C/75% RH)
• Testing intervals
• Test parameters (e.g., assay, degradation products, water content, pH)
• Acceptance criteria
• Responsibilities

The protocol is typically prepared by Quality Control and approved by Quality Assurance.

Stability chambers must be appropriately qualified, regularly calibrated, continuously monitored (temperature and relative humidity), and equipped with an alarm system. Appropriate contingency measures must be in place to address power failures or chamber malfunctions.

All analytical methods used in stability testing must be validated in accordance with applicable regulatory requirements.

Following marketing authorisation, at least one representative production batch per year should be included in the ongoing stability program, provided the product is manufactured during that period.

Recommended GMP Training Topics

For companies and professionals involved in planning, conducting, and evaluating stability studies – as well as for personnel in Quality Assurance and Regulatory Affairs – the following training topics are recommended:

• Fundamentals of ICH Q1A–Q1E
• Practical conduct of stability studies
• Statistical evaluation of stability data
• OOS and OOT management
• Ongoing stability programs and linkage to the Product Quality Review (PQR)
• Stability studies for biological products